• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[血管性水肿预防]

[Angioedema prophylaxis].

作者信息

Zampeli V, Magerl M

机构信息

Klinik für Dermatologie, Venerologie und Allergologie, Allergie-Centrum-Charité/ECARF, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.

出版信息

Hautarzt. 2019 Feb;70(2):107-115. doi: 10.1007/s00105-018-4345-9.

DOI:10.1007/s00105-018-4345-9
PMID:30656382
Abstract

Angioedema is a spontaneous, edematous swelling of the deep layers of the skin or mucous membrane. Angioedema in the respiratory tract is potentially life-threatening. The classification of angioedema into mast-cell-mediated (e. g. urticaria) or bradykinin-mediated (e. g. hereditary angioedema) is important for correct and rational treatment. Generally, two therapeutic strategies are available for angioedema treatment. On-demand treatment of angioedema symptoms that already have emerged aims to stop the further development of the attack and, thus, limits the severity and duration of the attack. This strategy is well established in the treatment of patients with hereditary angioedema, whereas in chronic spontaneous urticaria on-demand therapy plays no role in the guideline recommendations. In contrast, the therapeutic strategy of prophylaxis aims to prevent the occurrence of spontaneous and induced attacks as far as possible. Prophylaxis is the sole therapy strategy for chronic urticaria and is applied at all stages of the treatment algorithm. In the case of hereditary angioedema, on-demand therapy can be complemented by prophylaxis after careful and individual indication. In hereditary angioedema, prophylaxis is currently gaining in importance due to improved treatment options. Patients who use a prophylactic regime are much less likely to be forced to wait for the unpredictable occurrence of an attack and then to react with an on-demand treatment. Prophylactic treatment takes place at times determined by the patient himself, in contrast to treatment on an as-needed basis. The loss of unpredictability is a decisive moment in improving the quality of life.

摘要

血管性水肿是皮肤或黏膜深层的自发性水肿肿胀。呼吸道的血管性水肿有潜在生命危险。将血管性水肿分为肥大细胞介导型(如荨麻疹)或缓激肽介导型(如遗传性血管性水肿)对于正确合理的治疗很重要。一般来说,血管性水肿治疗有两种策略。对已出现的血管性水肿症状进行按需治疗旨在阻止发作的进一步发展,从而限制发作的严重程度和持续时间。这种策略在遗传性血管性水肿患者的治疗中已得到充分确立,而在慢性自发性荨麻疹中,按需治疗在指南推荐中不起作用。相比之下,预防治疗策略旨在尽可能预防自发性和诱发性发作的发生。预防是慢性荨麻疹的唯一治疗策略,并且应用于治疗方案的所有阶段。在遗传性血管性水肿中,经过仔细的个体化评估后,按需治疗可辅以预防治疗。在遗传性血管性水肿中,由于治疗选择的改善,预防目前变得越来越重要。与按需治疗相比,采用预防方案的患者不太可能被迫等待不可预测的发作发生然后进行按需治疗。预防性治疗在患者自己确定的时间进行,这是提高生活质量的一个决定性时刻。

相似文献

1
[Angioedema prophylaxis].[血管性水肿预防]
Hautarzt. 2019 Feb;70(2):107-115. doi: 10.1007/s00105-018-4345-9.
2
Nanofiltrated C1-esterase-inhibitor in the prophylactic treatment of bradykinin-mediated angioedema.纳米过滤的C1酯酶抑制剂在缓激肽介导的血管性水肿预防性治疗中的应用
Transfusion. 2016 May;56(5):1022-9. doi: 10.1111/trf.13462. Epub 2016 Jan 12.
3
Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate.用巴氏消毒的 C1 抑制剂浓缩物进行遗传性血管性水肿的长期预防。
Int Arch Allergy Immunol. 2011;154(4):356-9. doi: 10.1159/000321830. Epub 2010 Oct 26.
4
C1-esterase inhibitor (Cinryze) use in the treatment of pediatric hereditary angioedema.C1酯酶抑制剂(Cinryze)用于治疗儿童遗传性血管性水肿。
Immunotherapy. 2018 Jun;10(8):635-642. doi: 10.2217/imt-2017-0049. Epub 2018 Mar 23.
5
A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.红斑性结节性天疱疮期间 C1 抑制剂浓缩物在遗传性血管性水肿中的新预防作用。
Immunol Lett. 2017 Sep;189:90-93. doi: 10.1016/j.imlet.2017.05.015. Epub 2017 May 31.
6
Hereditary angioedema: an update on causes, manifestations and treatment.遗传性血管性水肿:病因、表现及治疗的最新进展
Br J Hosp Med (Lond). 2019 Jul 2;80(7):391-398. doi: 10.12968/hmed.2019.80.7.391.
7
A safety review of prophylaxis drugs for adolescent patients with hereditary angioedema.青少年遗传性血管性水肿患者预防药物的安全性综述。
Expert Opin Drug Saf. 2023 Jul-Dec;22(7):549-561. doi: 10.1080/14740338.2023.2226861. Epub 2023 Jun 21.
8
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.用于预防遗传性血管性水肿发作的皮下 C1 抑制剂的健康相关生活质量。
J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1733-1741.e3. doi: 10.1016/j.jaip.2017.12.039. Epub 2018 Jan 31.
9
The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.遗传性C1抑制剂缺乏所致血管性水肿治疗的安全性
Expert Opin Drug Saf. 2015;14(11):1725-36. doi: 10.1517/14740338.2015.1094053. Epub 2015 Oct 1.
10
Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).重组人C1酯酶抑制剂用于治疗因C1抑制剂缺乏所致的遗传性血管性水肿(C1-INH-HAE)。
Expert Rev Clin Immunol. 2015 Mar;11(3):319-27. doi: 10.1586/1744666X.2015.1012502. Epub 2015 Feb 10.

引用本文的文献

1
A Rare Case of Valsartan-Induced Angioedema.缬沙坦诱发血管性水肿1例罕见病例。
Cureus. 2025 Jun 9;17(6):e85623. doi: 10.7759/cureus.85623. eCollection 2025 Jun.

本文引用的文献

1
Omalizumab for Idiopathic Nonhistaminergic Angioedema: Evidence for Efficacy in 2 Patients.奥马珠单抗治疗特发性非组胺能性血管性水肿:2例患者的疗效证据
Case Reports Immunol. 2018 Jul 22;2018:8067610. doi: 10.1155/2018/8067610. eCollection 2018.
2
Montelukast reduces symptom severity and frequency in patients with angioedema-predominant chronic spontaneous urticaria.孟鲁司特可降低以血管性水肿为主的慢性自发性荨麻疹患者的症状严重程度和发作频率。
J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1403-1405. doi: 10.1016/j.jaip.2018.04.026. Epub 2018 May 5.
3
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
欧洲过敏研究学会/过敏标准委员会/欧洲皮肤病学会/世界变态反应组织荨麻疹指南:定义、分类、诊断和管理。
Allergy. 2018 Jul;73(7):1393-1414. doi: 10.1111/all.13397.
4
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update.《遗传性血管性水肿管理的国际 WAO/EAACI 指南——2017 年修订版》。
Allergy. 2018 Aug;73(8):1575-1596. doi: 10.1111/all.13384. Epub 2018 Mar 12.
5
Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment.C1抑制剂正常的遗传性血管性水肿:评估与治疗的最新进展
Immunol Allergy Clin North Am. 2017 Aug;37(3):571-584. doi: 10.1016/j.iac.2017.04.004.
6
Angioedema suppressed by a combination of anti-histamine and leukotriene modifier.血管性水肿通过抗组胺药和白三烯调节剂的联合使用得到抑制。
Allergy Asthma Clin Immunol. 2017 Jun 13;13:28. doi: 10.1186/s13223-017-0201-1. eCollection 2017.
7
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor.皮下注射 C1 抑制剂预防遗传性血管性水肿发作。
N Engl J Med. 2017 Mar 23;376(12):1131-1140. doi: 10.1056/NEJMoa1613627.
8
Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency.获得性 C1 抑制剂缺乏症患者血管性水肿的诊断、病程和治疗。
J Allergy Clin Immunol Pract. 2017 Sep-Oct;5(5):1307-1313. doi: 10.1016/j.jaip.2016.12.032. Epub 2017 Mar 9.
9
Treatment for hereditary angioedema with normal C1-INH and specific mutations in the F12 gene (HAE-FXII).用正常 C1-INH 和 F12 基因(HAE-FXII)中的特定突变治疗遗传性血管性水肿。
Allergy. 2017 Feb;72(2):320-324. doi: 10.1111/all.13076. Epub 2016 Dec 1.
10
Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.血清自身反应性可预测慢性自发性荨麻疹患者对奥马珠单抗治疗的反应时间。
J Allergy Clin Immunol. 2017 Mar;139(3):1059-1061.e1. doi: 10.1016/j.jaci.2016.07.047. Epub 2016 Nov 9.